ATLANTA, GA – – (Globe Newswire – June 10, 2024) – – A shareholder class action lawsuit has been filed against Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information, including allegations that: (i) Gritstone would be unable to launch the Phase 2b CORAL Study in the timeframe it had represented to investors; (ii) the foregoing would impair Gritstone’s ability to obtain external funding in connection with the Study, thereby negatively affecting Gritstone’s ability to maintain its balance sheet and cash position; and (iii) accordingly, Gritstone overstated its ability to successfully develop and commercialize its products.

If you bought Gritstone shares between March 9, 2023 and February 29, 2024, and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888)-508-6832, or you may visit the firm’s website at www.holzerlaw.com/case/gritstone-bio/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is August 6, 2024.